Actemra Is First Biologic Agent To Show Better Efficacy Than Methotrexate In RA

PARIS: The interleukin-6 receptor inhibitor Actemra (tocilizumab) achieves significantly greater reduction in the signs and symptoms of rheumatoid arthritis (RA) than the current standard of care, methotrexate, according to two international clinical trials reported this week at EULAR 2008, the Annual European Congress of Rheumatology.

More: continued here

Filed under: Arthritis on June 19th, 2008